Key Investor Takeaways
- BioLargo Inc. reported third-quarter revenue of US$1.09 million, about flat with the year earlier. Service revenue rose 72%, and the net loss narrowed 47% to US$3.82 million.
- CEO Dennis P. Calvert expects 2027 to be a commercial breakout year, with spending shifting from research and development to sales.
- Monthly operating cash use fell about 26% in the third quarter from the first half, and 77% of the capital raised this year came at the subsidiary level.
- Clyra Medical signed three ViaCLYR distributors and plans a national rollout of an additional product line with a confidential strategic partner in 2027.
- BioLargo launched its barebird consumer odor brand in October and is pursuing PFAS treatment work as settlements and industry demand widen the market.
- Oak Ridge Financial analyst Richard Ryan reiterated his "Buy" rating in a November 18 report.
BioLargo Sets Up 2027 as Its Sales Year
BioLargo Inc. (BLGO:OTCQX) expects 2027 to mark a commercial turning point as it shifts spending from research and development toward sales, according to its November 17 third-quarter results.
Revenue for the quarter ended September 30 totaled US$1.09 million, little changed from US$1.10 million a year earlier. However, service revenue rose 72%, while product revenue declined 32%.
The net loss narrowed 47% to US$3.82 million from US$7.24 million, primarily because the year-earlier quarter included a US$3.85 million credit loss expense. Excluding that expense, the net loss increased by US$429,000, reflecting higher operating and interest expenses, particularly at Clyra Medical as it builds infrastructure to prepare for its national launch of a new product line. The cleantech and life sciences company filed its Form 10-Q on November 16 and will skip a quarterly earnings call with its annual meeting scheduled just two weeks away.
Calvert: 'We've Prepared'
CEO Dennis P. Calvert said in an exclusive comment for Streetwise Reports that BioLargo spent heavily to be ready early, and that the payoff is now within reach.
"We've prepared. We've got real technology, real products ... with claims that are proven," Calvert said. "We've paid a price to be early in the cycle. Now the market's heading our direction."
He added that Clyra and barebird give the company something it hasn't had before. "Between the Clyra activity and now the barebird activity, we can look forward and say we can control our destiny like never before. And that's new," he said. "So yes, bullish on '27 for sure."
The cash numbers show some of that shift already under way. Operations used roughly US$736,000 a month in the third quarter, down about 26% from roughly US$996,000 a month in the first half. Over nine months, operating cash use totaled US$8.18 million.
In the release, Calvert said most of the work of building channels, supply chains and partnerships was funded inside the subsidiaries rather than the parent. Clyra Medical raised US$4.3 million, mainly through a debt offering, and the battery subsidiary BioLargo Energy Technologies, Inc. (BETI) sold US$487,000 in stock. Together, that was 77% of the capital raised this year.
Oak Ridge Financial analyst Richard Ryan reaffirmed his "Buy" rating on BioLargo in a November 18 update after the third-quarter results.
"These investments help build value to BioLargo stockholders as these companies progress with minimal dilution to BioLargo," Calvert said. The parent company also sold US$1.36 million in common stock, partly through its Clearthink purchase agreement. The corporate segment's nine-month operating loss fell 27% to US$2.2 million from US$3.03 million.
For the nine months, revenue was US$3.45 million versus US$7.15 million, mostly because product revenue fell 73% after BioLargo revoked Pooph's license in September 2025. Service revenue rose 23%. The nine-month net loss was US$11.23 million, about level with US$11.05 million a year earlier. Clyra accounted for US$6.4 million (57%) of that, as it spent on personnel, manufacturing, product development, and clinical work ahead of 2027.
Clyra and barebird Head to Market
Clyra spent 2026 building a distribution network for its ViaCLYR wound irrigation product, signing Advanced Solution for the U.S. market, Al-Hikma FZCO for international sales and Spartan Medical for U.S. government and military customers. In Q3, it also achieved a contractual milestone under an exclusive distribution agreement covering certain products.
BioLargo said positive clinician feedback is helping Clyra gain access to health systems nationwide. In 2027, Clyra plans to launch another product line nationally with a strategic partner whose identity remains confidential.
On the consumer side, BioLargo launched its barebird brand in October through its new subsidiary, BioLargo CPG LLC. The pet and laundry odor-control products are fragrance-free and, as the company puts it, "smell like nothing... on purpose." They use BioLargo's proprietary CupriDyne Clean technology, also deployed to control odors at landfills and waste facilities. The company plans to keep marketing costs down through AI-powered digital sales tools.
PFAS Demand Spreads Beyond Drinking Water
BioLargo's Aqueous Electrostatic Concentrator (AEC) has been treating municipal drinking water in Lake Stockholm, New Jersey, since January, with the Environmental Protection Agency and New Jersey regulators monitoring its performance.
Tonya Chandler, president of BioLargo Equipment Solutions & Technologies Inc., said demand for treatment is expanding as billions of dollars in lawsuit settlements are expected to fund cleanup at public water systems. Requirements are also "spreading to wastewater, landfill leachate, biosolids, industrial pre-treatment and shorter-chain compounds," she said. "Increasingly, they're choosing to treat at the source now, regardless of when federal enforcement arrives."
BioLargo has submitted bids and proposals, brought several prominent industry experts on board and begun partnership discussions with leading companies seeking to fill gaps in their PFAS treatment offerings. Its engineering team increased revenue 23% while supporting the PFAS and Cellinity projects.
Two development-stage businesses, BioLargo Energy, focused on its Cellinity industrial grid-scale battery, and Tu Nipi, which develops water treatment solutions for Canadian oil sands tailings, are also discussing potential investments and expansion plans with strategic partners.
BioLargo will hold its annual stockholder meeting on December 1 at 10 a.m. Pacific Time in Aliso Viejo, California.
Analyst Sees 'Many Shots on Goal'
Oak Ridge Financial analyst Richard Ryan reaffirmed his "Buy" rating on BioLargo in a November 18 update after the third-quarter results. "Noticeable progress is occurring across all BLGO's divisions," he wrote.
Ryan said BioLargo's technologies serve very large global markets, giving it "many shots on goal." He described the business model as "a hub and spoke format." BioLargo invents or acquires a product, proves it out, partners with third parties, and commercializes it. Running technologies through operating subsidiaries "diversifies overall risk, maintains high levels of segment ownership while providing solutions to diversified, high-growth end markets," he wrote.
He sees Clyra Medical and BioLargo's consumer products as closest to commercial inflection. ViaCLYR is FDA 510(k) cleared, and Clyra's three distribution channels reach about 6,100 hospitals, 6,300 ambulatory surgery centers and 2,200 specialty wound care clinics in the U.S., Ryan noted. After 14 years and upwards of US$20 million invested, he wrote, Clyra appears to be on the cusp of commercialization.
BioLargo has always owned the CupriDyne technology behind its pet odor products, which generated more than US$125 million in pet-care sales under its earlier licensing deal, Ryan noted. With barebird, it now owns the brand too. He expects revenue to nearly triple to about US$13 million in 2027 from an estimated US$4.7 million this year, with barebird contributing from the first quarter.
Ryan also noted that engineering revenue rose 72% to US$563,000 in the quarter on more fixed-fee work at U.S. Air Force bases and an environmental remediation project. Gross margin improved to 47.3% from about 34% a year earlier.
Three Markets Already Spending Big
BioLargo's three closest-to-market businesses target industries with substantial existing spending and growing demand.
The pet market is one. U.S. pet industry spending reached US$158 billion in 2025 and is expected to rise to US$165 billion this year, according to the American Pet Products Association. The association reports that 95 million U.S. households own at least one pet, with dog ownership reaching 53% of households in 2025 and cat ownership 39%. Odor control represents a sizable market within the industry. The global pet odor control and cleanup products market was valued at US$14.61 billion in 2025 and is projected to reach US$19.33 billion by 2034, according to Fortune Business Insights. North America accounts for roughly half of global sales.
PFAS remediation is another growth market, with legal settlements helping fund cleanup. 3M agreed to pay U.S. public water systems between US$10.5 billion and US$12.5 billion through 2036, CBS News reported, to help cover PFAS testing and removal. DuPont, Chemours and Corteva reached a separate settlement of approximately US$1.18 billion with about 300 drinking water providers. Meanwhile, the global PFAS remediation market was valued at US$4.25 billion in 2025 and is projected to reach US$14.42 billion by 2036, with an estimated compound annual growth rate of 11.4% from 2026 through 2036, according to Meticulous Research. North America is expected to remain the largest regional market.
Wound care is the third opportunity. The global wound irrigation systems market was valued at US$315 million in 2024 and is projected to reach US$433.7 million by 2034, according to Global Market Insights. Rising rates of chronic wounds are driving demand for improved wound management.
Calvert sees a common opening across these markets. "In every market we serve — PFAS removal, grid-scale energy storage, infection control and wound care, industrial and household odor control — customers have lived with the drawbacks of the incumbent technologies because there hasn't been a better option," he said. "Our products and solutions are designed to be that option — for our customers and for the partners who sell them."
Ownership and Share Structure1
Strategic entities hold about 7.14% of BioLargo, management and insiders own approximately 6.82%, and institutions hold about 0.04%, with retail investors accounting for the balance.
The largest disclosed holders include IOWC Technologies, Inc. (6.67%), Dennis P. Calvert (3.33%), Jack B. Strommen (1.47%), Kenneth R. Code (1.29%), and First American Trust, FSB (0.04%).
The company has roughly 338.44 million shares outstanding as of November 12 and a market capitalization of about US$22.8 million.
No verified insider open-market buys or sells were found for the last six months.
BioLargo had 25,666,478 warrants outstanding as of September 30, according to its Form 10-Q. No historical share restructures were found.
Common Questions from Investors
Why does BioLargo say 2027 will be a breakout year?
The company says it has built the sales channels, supply chain, and partnerships it needs, mostly with money raised inside its subsidiaries. In 2027, it expects to shift spending from research and development toward generating sales.
How did BioLargo perform in the third quarter?
Revenue was US$1.09 million, compared with US$1.10 million a year earlier. Service revenue rose 72%, while product revenue fell 32%. The net loss narrowed 47% to US$3.82 million, mostly because the year-ago quarter included a credit loss expense.
Is BioLargo spending less cash?
In the third quarter, yes. Operations used roughly US$736,000 a month in the third quarter, compared with about US$996,000 a month in the first half, a drop of about 26%. Separately, the operating loss of BioLargo's corporate segment, which includes non-cash expenses, declined 27% for the nine months to US$2.2 million from US$3.03 million.
What is Clyra Medical planning for 2027?
Clyra sells its ViaCLYR wound irrigation product through Advanced Solution in the U.S., Al-Hikma FZCO internationally, and Spartan Medical for U.S. government and military customers. In 2027, it plans a national rollout of an additional product line with a confidential strategic partner.
What is barebird?
barebird is BioLargo's own line of fragrance-free pet and laundry odor products. It launched in October through a new subsidiary, BioLargo CPG LLC, and uses the company's CupriDyne Clean technology.
Where does BioLargo's PFAS business stand?
Since January, BioLargo's Aqueous Electrostatic Concentrator has been treating drinking water in Lake Stockholm, New Jersey. The company has submitted bids and is in partnership talks with industry-leading firms. It sees demand spreading to wastewater, landfill leachate, and industrial treatment.
What do analysts say about BioLargo?
Oak Ridge Financial analyst Richard Ryan reiterated his "Buy" rating in his November 19 report.
When is BioLargo's annual meeting?
It's on December 1 at 10 a.m. Pacific Time in Aliso Viejo, California.
| Want to be the first to know about interesting Technology, Healthcare Services and Special Situations investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- BioLargo Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc. and Clyra Medical.
- Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
Ownership percentages, named holders, share count, market capitalization, and the 52-week range for BioLargo were compiled from company public filings and investor materials, exchange notices, insider-trade reports (SEDI / equivalent), and third-party data providers. Figures are as of 2026-11-17 unless a source was dated earlier. Pie slices are normalized to 100% of basic shares outstanding; retail is the residual after disclosed institutions, management, insiders, and strategic holders. Warrant terms are current outstanding series only. Restructures are historical consolidations, splits, and symbol or name changes. Insider buying and selling covers open-market trades from the prior six months through 2026-11-17 and excludes option exercises. These are public-source estimates and can differ from a later official register.


















































